Cited by

• Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication.

  Zai G, Müller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, Kennedy JL. Zai G, et al. Psychopharmacology (Berl). 2006 Oct;188(2):171-82. doi: 10.1007/s00213-006-0482-4. Epub 2006 Aug 24. Psychopharmacology (Berl). 2006. PMID: 16932925
• Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

  Miyaoka T, Furuya M, Horiguchi J, Wake R, Hashioka S, Tohyama M, Mori N, Minabe Y, Iyo M, Ueno S, Ezoe S, Murotani K, Hoshino S, Seno H. Miyaoka T, et al. Psychopharmacology (Berl). 2015 Jan;232(1):155-64. doi: 10.1007/s00213-014-3645-8. Epub 2014 Jun 13. Psychopharmacology (Berl). 2015. PMID: 24923986 Clinical Trial.
• Accessing Gene Expression in Treatment-Resistant Schizophrenia.

  Moretti PN, Ota VK, Gouvea ES, Pedrini M, Santoro ML, Talarico F, Spindola LM, Carvalho CM, Noto C, Xavier G, Brietzke E, Gadelha A, Bressan R, Mari J, Belangero S. Moretti PN, et al. Mol Neurobiol. 2018 Aug;55(8):7000-7008. doi: 10.1007/s12035-018-0876-4. Epub 2018 Jan 26. Mol Neurobiol. 2018. PMID: 29374346
• Seroquel: biochemical profile of a potential atypical antipsychotic.

  Saller CF, Salama AI. Saller CF, et al. Psychopharmacology (Berl). 1993;112(2-3):285-92. doi: 10.1007/BF02244923. Psychopharmacology (Berl). 1993. PMID: 7871032
• Revisiting the Therapeutic Potential of Bothrops jararaca Venom: Screening for Novel Activities Using Connectivity Mapping.

  Nicolau CA, Prorock A, Bao Y, Neves-Ferreira AGDC, Valente RH, Fox JW. Nicolau CA, et al. Toxins (Basel). 2018 Feb 6;10(2):69. doi: 10.3390/toxins10020069. Toxins (Basel). 2018. PMID: 29415440 Free PMC article.